{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T22:32:50Z","timestamp":1790548370204,"version":"4.1.0"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurogenetics"],"DOI":"10.1007\/s10048-026-00887-2","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T03:58:10Z","timestamp":1771646290000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Gene therapy for huntington\u2019s disease: advances, challenges, and future perspectives"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7944-2122","authenticated-orcid":false,"given":"Riya","family":"Kaushal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2127-7873","authenticated-orcid":false,"given":"Mohit","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3102-0069","authenticated-orcid":false,"given":"Sourabh","family":"Kosey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7842-110X","authenticated-orcid":false,"given":"Madhaw","family":"Dwivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"key":"887_CR1","doi-asserted-by":"publisher","unstructured":"Ghosh R, Tabrizi SJ (2018) Huntington disease. Handb Clin Neurol, vol 147, Elsevier, pp 255\u201378. https:\/\/doi.org\/10.1016\/B978-0-444-63233-3.00017-8","DOI":"10.1016\/B978-0-444-63233-3.00017-8"},{"key":"887_CR2","doi-asserted-by":"publisher","first-page":"101385","DOI":"10.1016\/j.arr.2021.101385","volume":"70","author":"E Fields","year":"2021","unstructured":"Fields E, Vaughan E, Tripu D, Lim I, Shrout K, Conway J et al (2021) Gene targeting techniques for huntington\u2019s disease. Ageing Res Rev 70:101385. https:\/\/doi.org\/10.1016\/j.arr.2021.101385","journal-title":"Ageing Res Rev"},{"key":"887_CR3","doi-asserted-by":"publisher","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","volume":"1","author":"GP Bates","year":"2015","unstructured":"Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR et al (2015) Huntington disease. Nat Rev Dis Primer 1:15005. https:\/\/doi.org\/10.1038\/nrdp.2015.5","journal-title":"Nat Rev Dis Primer"},{"key":"887_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ebiom.2018.03.031","volume":"31","author":"JK Lee","year":"2018","unstructured":"Lee JK, Conrad A, Epping E, Mathews K, Magnotta V, Dawson JD et al (2018) Effect of Trinucleotide Repeats in the Huntington\u2019s Gene on Intelligence. EBioMedicine 31:47\u201353 https:\/\/doi.org\/10.1016\/j.ebiom.2018.03.031","journal-title":"EBioMedicine"},{"key":"887_CR5","doi-asserted-by":"publisher","unstructured":"Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, Nance M, Ross CA, Scahill RI, Wetzel R, Wild EJ (2017) Genetics of Huntington\u2019s disease. In van den Heuvel MAHA, Ross CA (eds), Handbook of Clinical Neurology (vol 144, pp 3\u201314). Elsevier. https:\/\/doi.org\/10.1016\/B978-0-12-801893-4.00001-6","DOI":"10.1016\/B978-0-12-801893-4.00001-6"},{"key":"887_CR6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1399-0004.2004.00241.x","volume":"65","author":"D Langbehn","year":"2004","unstructured":"Langbehn D, Brinkman R, Falush D, Paulsen J, Hayden M, on behalf of an International Huntington\u2019s Disease Collaborative Group (2004) A new model for prediction of the age of onset and penetrance for huntington\u2019s disease based on CAG length. Clin Genet 65:267\u2013277. https:\/\/doi.org\/10.1111\/j.1399-0004.2004.00241.x","journal-title":"Clin Genet"},{"key":"887_CR7","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/0092-8674(95)90542-1","volume":"81","author":"J Nasir","year":"1995","unstructured":"Nasir J, Floresco SB, O\u2019Kusky JR, Diewert VM, Richman JM, Zeisler J et al (1995) Targeted disruption of the huntington\u2019s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81:811\u2013823. https:\/\/doi.org\/10.1016\/0092-8674(95)90542-1","journal-title":"Cell"},{"key":"887_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.tins.2005.01.002","volume":"28","author":"LF Barros","year":"2005","unstructured":"Barros LF, Porras OH, Bittner CX (2005) Why glucose transport in the brain matters for PET. Trends Neurosci 28:117\u2013119. https:\/\/doi.org\/10.1016\/j.tins.2005.01.002","journal-title":"Trends Neurosci"},{"key":"887_CR9","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","volume":"74","author":"HB Kordasiewicz","year":"2012","unstructured":"Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, McAlonis MM, Pytel KA et al (2012) Sustained therapeutic reversal of huntington\u2019s disease by transient repression of Huntingtin synthesis. Neuron 74:1031\u20131044. https:\/\/doi.org\/10.1016\/j.neuron.2012.05.009","journal-title":"Neuron"},{"key":"887_CR10","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1093\/nar\/gkaa024","volume":"48","author":"A Gao","year":"2020","unstructured":"Gao A, Vasilyev N, Kaushik A, Duan W, Serganov A (2020) Principles of RNA and nucleotide discrimination by the RNA processing enzyme RppH. Nucleic Acids Res 48:3776\u20133788. https:\/\/doi.org\/10.1093\/nar\/gkaa024","journal-title":"Nucleic Acids Res"},{"key":"887_CR11","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.cell.2015.07.003","volume":"162","author":"J-M Lee","year":"2015","unstructured":"Lee J-M, Wheeler VC, Chao MJ, Vonsattel JPG, Pinto RM, Lucente D et al (2015) Identification of genetic factors that modify clinical onset of huntington\u2019s disease. Cell 162:516\u2013526. https:\/\/doi.org\/10.1016\/j.cell.2015.07.003","journal-title":"Cell"},{"key":"887_CR12","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.cell.2019.06.036","volume":"178","author":"J-M Lee","year":"2019","unstructured":"Lee J-M, Correia K, Loupe J, Kim K-H, Barker D, Hong EP et al (2019) CAG repeat not polyglutamine length determines timing of huntington\u2019s disease onset. Cell 178:887\u2013900e14. https:\/\/doi.org\/10.1016\/j.cell.2019.06.036","journal-title":"Cell"},{"key":"887_CR13","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/nrd.2018.109","volume":"17","author":"B Boland","year":"2018","unstructured":"Boland B, Yu WH, Corti O, Mollereau B, Henriques A, Bezard E et al (2018) Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing. Nat Rev Drug Discov 17:660\u2013688. https:\/\/doi.org\/10.1038\/nrd.2018.109","journal-title":"Nat Rev Drug Discov"},{"key":"887_CR14","doi-asserted-by":"publisher","first-page":"e02506882276317","DOI":"10.2174\/0102506882276317240111103545","volume":"05","author":"K Suryavanshi","year":"2024","unstructured":"Suryavanshi K, Sharma AK, Murti Y, Kumari V, Shanker Shukla K, Kulshreshtha M (2024) Molecular pathways and treatment updates on huntington\u2019s disease withspecial preference to juvenile phase: A comprehensive review. New Emir Med J 05:e02506882276317. https:\/\/doi.org\/10.2174\/0102506882276317240111103545","journal-title":"New Emir Med J"},{"key":"887_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","volume":"10","author":"CA Ross","year":"2011","unstructured":"Ross CA, Tabrizi SJ (2011) Huntington\u2019s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 10:83\u201398. https:\/\/doi.org\/10.1016\/S1474-4422(10)70245-3","journal-title":"Lancet Neurol"},{"key":"887_CR16","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/aps.2018.11","volume":"39","author":"RJ Harding","year":"2018","unstructured":"Harding RJ, Tong Y (2018) Proteostasis in huntington\u2019s disease: disease mechanisms and therapeutic opportunities. Acta Pharmacol Sin 39:754\u2013769. https:\/\/doi.org\/10.1038\/aps.2018.11","journal-title":"Acta Pharmacol Sin"},{"key":"887_CR17","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/nrn1806","volume":"6","author":"E Cattaneo","year":"2005","unstructured":"Cattaneo E, Zuccato C, Tartari M (2005) Normal Huntingtin function: an alternative approach to huntington\u2019s disease. Nat Rev Neurosci 6:919\u2013930. https:\/\/doi.org\/10.1038\/nrn1806","journal-title":"Nat Rev Neurosci"},{"key":"887_CR18","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","volume":"89","author":"F Saudou","year":"2016","unstructured":"Saudou F, Humbert S (2016) The biology of Huntingtin. Neuron 89:910\u2013926. https:\/\/doi.org\/10.1016\/j.neuron.2016.02.003","journal-title":"Neuron"},{"key":"887_CR19","doi-asserted-by":"publisher","first-page":"5820","DOI":"10.1038\/s41467-020-19530-5","volume":"11","author":"K Bulaklak","year":"2020","unstructured":"Bulaklak K, Gersbach CA (2020) The once and future gene therapy. Nat Commun 11:5820. https:\/\/doi.org\/10.1038\/s41467-020-19530-5","journal-title":"Nat Commun"},{"key":"887_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jconrel.2016.05.044","volume":"235","author":"C Saraiva","year":"2016","unstructured":"Saraiva C, Pra\u00e7a C, Ferreira R, Santos T, Ferreira L, Bernardino L (2016) Nanoparticle-mediated brain drug delivery: overcoming blood\u2013brain barrier to treat neurodegenerative diseases. J Controlled Release 235:34\u201347. https:\/\/doi.org\/10.1016\/j.jconrel.2016.05.044","journal-title":"J Controlled Release"},{"key":"887_CR21","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.3390\/biomedicines10061432","volume":"10","author":"A Jurcau","year":"2022","unstructured":"Jurcau A (2022) Molecular pathophysiological mechanisms in huntington\u2019s disease. Biomedicines 10:1432. https:\/\/doi.org\/10.3390\/biomedicines10061432","journal-title":"Biomedicines"},{"key":"887_CR22","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.brainresbull.2019.05.024","volume":"150","author":"DL Puhl","year":"2019","unstructured":"Puhl DL, D\u2019Amato AR, Gilbert RJ (2019) Challenges of gene delivery to the central nervous system and the growing use of biomaterial vectors. Brain Res Bull 150:216\u2013230. https:\/\/doi.org\/10.1016\/j.brainresbull.2019.05.024","journal-title":"Brain Res Bull"},{"key":"887_CR23","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1016\/0006-2952(75)90405-0","volume":"24","author":"MM Ris","year":"1975","unstructured":"Ris MM, Deitrich RA, Von Wartburg JP (1975) Inhibition of aldehyde reductase isoenzymes in human and rat brain. Biochem Pharmacol 24:1865\u20131869. https:\/\/doi.org\/10.1016\/0006-2952(75)90405-0","journal-title":"Biochem Pharmacol"},{"key":"887_CR24","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","volume":"380","author":"SJ Tabrizi","year":"2019","unstructured":"Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA et al (2019) Targeting Huntingtin expression in patients with huntington\u2019s disease. N Engl J Med 380:2307\u20132316. https:\/\/doi.org\/10.1056\/NEJMoa1900907","journal-title":"N Engl J Med"},{"key":"887_CR25","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1073\/pnas.91.6.2076","volume":"91","author":"RH Bobo","year":"1994","unstructured":"Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH (1994) Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci 91:2076\u20132080. https:\/\/doi.org\/10.1073\/pnas.91.6.2076","journal-title":"Proc Natl Acad Sci"},{"key":"887_CR26","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/j.ymthe.2018.06.021","volume":"26","author":"MM Evers","year":"2018","unstructured":"Evers MM, Miniarikova J, Juhas S, Vall\u00e8s A, Bohuslavova B, Juhasova J et al (2018) AAV5-miHTT gene therapy demonstrates broad distribution and strong human mutant Huntingtin Lowering in a huntington\u2019s disease minipig model. Mol Ther 26:2163\u20132177. https:\/\/doi.org\/10.1016\/j.ymthe.2018.06.021","journal-title":"Mol Ther"},{"key":"887_CR27","doi-asserted-by":"publisher","unstructured":"Cavazza A, Hendel A, Bak RO, Rio P, G\u00fcell M, Lain\u0161\u010dek D et al (2023) Progress and harmonization of gene editing to treat human diseases: Proceeding of COST Action CA21113 GenE-HumDi. Mol Ther Nucleic Acids. 34:102066 https:\/\/doi.org\/10.1016\/j.omtn.2023.102066","DOI":"10.1016\/j.omtn.2023.102066"},{"key":"887_CR28","doi-asserted-by":"publisher","first-page":"785703","DOI":"10.3389\/fncel.2021.785703","volume":"15","author":"H Komatsu","year":"2021","unstructured":"Komatsu H (2021) Innovative therapeutic approaches for huntington\u2019s disease: from nucleic acids to GPCR-Targeting small molecules. Front Cell Neurosci 15:785703. https:\/\/doi.org\/10.3389\/fncel.2021.785703","journal-title":"Front Cell Neurosci"},{"key":"887_CR29","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/35888","volume":"391","author":"A Fire","year":"1998","unstructured":"Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specific genetic interference by double-stranded RNA in caenorhabditis elegans. Nature 391:806\u2013811. https:\/\/doi.org\/10.1038\/35888","journal-title":"Nature"},{"key":"887_CR30","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","volume":"116","author":"DP Bartel","year":"2004","unstructured":"Bartel DP, MicroRNAs (2004) Cell 116:281\u2013297. https:\/\/doi.org\/10.1016\/S0092-8674(04)00045-5","journal-title":"Cell"},{"key":"887_CR31","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","volume":"136","author":"DP Bartel","year":"2009","unstructured":"Bartel DP, MicroRNAs (2009) Target recognition and regulatory functions. Cell 136:215\u2013233. https:\/\/doi.org\/10.1016\/j.cell.2009.01.002","journal-title":"Cell"},{"key":"887_CR32","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrm3838","volume":"15","author":"M Ha","year":"2014","unstructured":"Ha M, Kim VN (2014) Regulation of MicroRNA biogenesis. Nat Rev Mol Cell Biol 15:509\u2013524. https:\/\/doi.org\/10.1038\/nrm3838","journal-title":"Nat Rev Mol Cell Biol"},{"key":"887_CR33","unstructured":"RNA silencing in plants | (2025) Nature n.d. https:\/\/www.nature.com\/articles\/nature02874"},{"key":"887_CR34","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/35078107","volume":"411","author":"SM Elbashir","year":"2001","unstructured":"Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494\u2013498. https:\/\/doi.org\/10.1038\/35078107","journal-title":"Nature"},{"key":"887_CR35","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/s1097-2765(02)00541-5","volume":"9","author":"Y Zeng","year":"2002","unstructured":"Zeng Y, Wagner EJ, Cullen BR (2002) Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell 9:1327\u20131333. https:\/\/doi.org\/10.1016\/s1097-2765(02)00541-5","journal-title":"Mol Cell"},{"key":"887_CR36","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1038\/ng1650","volume":"37","author":"JM Silva","year":"2005","unstructured":"Silva JM, Li MZ, Chang K, Ge W, Golding MC, Rickles RJ et al (2005) Second-generation ShRNA libraries covering the mouse and human genomes. Nat Genet 37:1281\u20131288. https:\/\/doi.org\/10.1038\/ng1650","journal-title":"Nat Genet"},{"key":"887_CR37","doi-asserted-by":"publisher","first-page":"5820","DOI":"10.1073\/pnas.0501507102","volume":"102","author":"SQ Harper","year":"2005","unstructured":"Harper SQ, Staber PD, He X, Eliason SL, Martins IH, Mao Q et al (2005) RNA interference improves motor and neuropathological abnormalities in a huntington\u2019s disease mouse model. Proc Natl Acad Sci U S A 102:5820\u20135825. https:\/\/doi.org\/10.1073\/pnas.0501507102","journal-title":"Proc Natl Acad Sci U S A"},{"key":"887_CR38","doi-asserted-by":"publisher","first-page":"5868","DOI":"10.1073\/pnas.0801775105","volume":"105","author":"JL McBride","year":"2008","unstructured":"McBride JL, Boudreau RL, Harper SQ, Staber PD, Monteys AM, Martins I et al (2008) Artificial MiRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci U S A 105:5868\u20135873. https:\/\/doi.org\/10.1073\/pnas.0801775105","journal-title":"Proc Natl Acad Sci U S A"},{"key":"887_CR39","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.omtm.2019.03.002","volume":"13","author":"EA Spronck","year":"2019","unstructured":"Spronck EA, Brouwers CC, Vall\u00e8s A, de Haan M, Petry H, van Deventer SJ et al (2019) AAV5-miHTT gene therapy demonstrates sustained Huntingtin Lowering and functional improvement in huntington disease mouse models. Mol Ther Methods Clin Dev 13:334\u2013343. https:\/\/doi.org\/10.1016\/j.omtm.2019.03.002","journal-title":"Mol Ther Methods Clin Dev"},{"key":"887_CR40","unstructured":"UniQure Biopharma B.V. A Phase 1\/2, Randomized, Double-Blind, Sham Control and Open-Label Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT-130) in Early Manifest Huntington\u2019s Disease. clinicaltrials.gov;2025"},{"key":"887_CR41","unstructured":"uniQure Announces Positive Topline Results from Pivotal Phase I\/II Study of AMT-130 (2025) in Patients with Huntington\u2019s Disease | uniqure BV n.d. https:\/\/uniqure.gcs-web.com\/news-releases\/news-release-details\/uniqure-announces-positive-topline-results-pivotal-phase-iii"},{"issue":"11","key":"887_CR42","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nmat3765","volume":"12","author":"R Kanasty","year":"2013","unstructured":"Kanasty R, Dorkin JR, Vegas A, Anderson D (2013) Delivery materials for SiRNA therapeutics. Nat Mater 12(11):967\u2013977. https:\/\/doi.org\/10.1038\/nmat3765","journal-title":"Nat Mater"},{"issue":"1","key":"887_CR43","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nbt.1515","volume":"27","author":"KD Foust","year":"2009","unstructured":"Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK (2009) Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 27(1):59\u201365. https:\/\/doi.org\/10.1038\/nbt.1515","journal-title":"Nat Biotechnol"},{"issue":"2","key":"887_CR44","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nbt.3440","volume":"34","author":"BE Deverman","year":"2016","unstructured":"Deverman BE, Pravdo PL, Simpson BP, Kumar SR, Chan KY, Banerjee A, Wu WL, Yang B, Huber N, Pasca SP, Gradinaru V (2016) Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol 34(2):204\u2013209. https:\/\/doi.org\/10.1038\/nbt.3440","journal-title":"Nat Biotechnol"},{"issue":"1","key":"887_CR45","doi-asserted-by":"publisher","first-page":"GE01","DOI":"10.7860\/JCDR\/2015\/10443.5394","volume":"9","author":"M Ramamoorth","year":"2015","unstructured":"Ramamoorth M, Narvekar A (2015) Non viral vectors in gene therapy- an overview. J Clin Diagn Research: JCDR 9(1):GE01\u2013GE6. https:\/\/doi.org\/10.7860\/JCDR\/2015\/10443.5394","journal-title":"J Clin Diagn Research: JCDR"},{"key":"887_CR46","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1093\/brain\/awr333","volume":"135","author":"R Grondin","year":"2012","unstructured":"Grondin R, Kaytor MD, Ai Y, Nelson PT, Thakker DR, Heisel J et al (2012) Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum. Brain 135:1197\u20131209. https:\/\/doi.org\/10.1093\/brain\/awr333","journal-title":"Brain"},{"issue":"3","key":"887_CR47","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1038\/mtna.2016.7","volume":"5","author":"J Miniarikova","year":"2016","unstructured":"Miniarikova J, Zanella I, Huseinovic A, van der Zon T, Hanemaaijer E, Martier R, Koornneef A, Southwell AL, Hayden MR, van Deventer SJ, Petry H, Konstantinova P (2016) Design, Characterization, and lead selection of therapeutic MiRNAs targeting Huntingtin for development of gene therapy for huntington\u2019s Disease. Molecular therapy. Nucleic Acids 5(3):e297. https:\/\/doi.org\/10.1038\/mtna.2016.7","journal-title":"Nucleic Acids"},{"key":"887_CR48","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/gt.2017.71","volume":"24","author":"J Miniarikova","year":"2017","unstructured":"Miniarikova J, Zimmer V, Martier R, Brouwers CC, Pythoud C, Richetin K et al (2017) AAV5-miHTT gene therapy demonstrates suppression of mutant Huntingtin aggregation and neuronal dysfunction in a rat model of huntington\u2019s disease. Gene Ther 24:630\u2013639. https:\/\/doi.org\/10.1038\/gt.2017.71","journal-title":"Gene Ther"},{"issue":"4","key":"887_CR49","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.ymthe.2005.05.006","volume":"12","author":"E Rodriguez-Lebron","year":"2005","unstructured":"Rodriguez-Lebron E, Denovan-Wright EM, Nash K, Lewin AS, Mandel RJ (2005) Intrastriatal rAAV-mediated delivery of anti-huntingtin ShRNAs induces partial reversal of disease progression in R6\/1 huntington\u2019s disease Transgenic mice. Mol Therapy: J Am Soc Gene Therapy 12(4):618\u2013633. https:\/\/doi.org\/10.1016\/j.ymthe.2005.05.006","journal-title":"Mol Therapy: J Am Soc Gene Therapy"},{"key":"887_CR50","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.neuron.2019.01.039","volume":"101","author":"SJ Tabrizi","year":"2019","unstructured":"Tabrizi SJ, Ghosh R, Leavitt BR (2019) Huntingtin Lowering strategies for disease modification in huntington\u2019s disease. Neuron 101:801\u2013819","journal-title":"Neuron"},{"issue":"8","key":"887_CR51","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/s41587-019-0205-0","volume":"37","author":"JF Alterman","year":"2019","unstructured":"Alterman JF, Godinho BMDC, Hassler MR, Ferguson CM, Echeverria D, Sapp E, Haraszti RA, Coles AH, Conroy F, Miller R, Roux L, Yan P, Knox EG, Turanov AA, King RM, Gernoux G, Mueller C, Gray-Edwards HL, Moser RP, Bishop NC, Khvorova A (2019) A divalent SiRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system. Nat Biotechnol 37(8):884\u2013894. https:\/\/doi.org\/10.1038\/s41587-019-0205-0","journal-title":"Nat Biotechnol"},{"key":"887_CR52","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","volume":"14","author":"C Rinaldi","year":"2018","unstructured":"Rinaldi C, Wood MJA (2018) Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol 14:9\u201321","journal-title":"Nat Rev Neurol"},{"key":"887_CR53","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","volume":"87","author":"RS Geary","year":"2015","unstructured":"Geary RS, Norris D, Yu R, Bennett CF (2015) Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev 87:46\u201351. https:\/\/doi.org\/10.1016\/j.addr.2015.01.008","journal-title":"Adv Drug Deliv Rev"},{"key":"887_CR54","doi-asserted-by":"publisher","first-page":"e16140","DOI":"10.1111\/ene.16140","volume":"31","author":"A Saini","year":"2024","unstructured":"Saini A, Chawla PA (2024) Breaking barriers with tofersen: enhancing therapeutic opportunities in amyotrophic lateral sclerosis. Eur J Neurol 31:e16140. https:\/\/doi.org\/10.1111\/ene.16140","journal-title":"Eur J Neurol"},{"key":"887_CR55","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s40265-024-02024-5","volume":"84","author":"T Nie","year":"2024","unstructured":"Nie T, Correction (2024) Eplontersen: first approval. Drugs 84:489\u2013489. https:\/\/doi.org\/10.1007\/s40265-024-02024-5","journal-title":"Drugs"},{"key":"887_CR56","first-page":"112","volume":"374","author":"AE\u2013E Aly","year":"2023","unstructured":"Aly AE\u2013E, Caron NS, Findlay Black H, Schmidt ME, Anderson C, Baddeley HJE et al (2023) Delivery of mutant huntingtin\u2013lowering antisense oligonucleotides to the brain by intranasally administered Apolipoprotein A\u2013I nanodisks. J Control Release 374:112\u2013124","journal-title":"J Control Release"},{"issue":"9","key":"887_CR57","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/j.ymthe.2017.06.002","volume":"25","author":"XH Liang","year":"2017","unstructured":"Liang XH, Sun H, Nichols JG, Crooke ST (2017) RNase H1-Dependent antisense oligonucleotides are robustly active in directing RNA cleavage in both the cytoplasm and the nucleus. Mol Therapy: J Am Soc Gene Therapy 25(9):2075\u20132092. https:\/\/doi.org\/10.1016\/j.ymthe.2017.06.002","journal-title":"Mol Therapy: J Am Soc Gene Therapy"},{"issue":"10","key":"887_CR58","doi-asserted-by":"publisher","first-page":"e108625","DOI":"10.1371\/journal.pone.0108625","volume":"9","author":"TA Vickers","year":"2014","unstructured":"Vickers TA, Crooke ST (2014) Antisense oligonucleotides capable of promoting specific target mRNA reduction via competing RNase H1-Dependent and independent mechanisms. PLoS ONE 9(10):e108625. https:\/\/doi.org\/10.1371\/journal.pone.0108625","journal-title":"PLoS ONE"},{"key":"887_CR59","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S1474-4422(17)30280-6","volume":"16","author":"EJ Wild","year":"2017","unstructured":"Wild EJ, Tabrizi SJ (2017) Therapies targeting DNA and RNA in huntington\u2019s disease. Lancet Neurol 16:837\u2013847. https:\/\/doi.org\/10.1016\/S1474-4422(17)30280-6","journal-title":"Lancet Neurol"},{"issue":"16","key":"887_CR60","doi-asserted-by":"publisher","first-page":"13021","DOI":"10.3390\/ijms241613021","volume":"24","author":"A Jiang","year":"2023","unstructured":"Jiang A, Handley RR, Lehnert K, Snell RG (2023) From pathogenesis to therapeutics: A review of 150 years of huntington\u2019s disease research. Int J Mol Sci 24(16):13021. https:\/\/doi.org\/10.3390\/ijms241613021","journal-title":"Int J Mol Sci"},{"issue":"2","key":"887_CR61","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/nar\/gkaa1235","volume":"49","author":"P Jafar-Nejad","year":"2021","unstructured":"Jafar-Nejad P, Powers B, Soriano A, Zhao H, Norris DA, Matson J, DeBrosse-Serra B, Watson J, Narayanan P, Chun SJ, Mazur C, Kordasiewicz H, Swayze EE, Rigo F (2021) The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration. Nucleic Acids Res 49(2):657\u2013673. https:\/\/doi.org\/10.1093\/nar\/gkaa1235","journal-title":"Nucleic Acids Res"},{"key":"887_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/mt.2014.227","volume":"23","author":"S Yl\u00e4-Herttuala","year":"2015","unstructured":"Yl\u00e4-Herttuala S (2015) The molecular therapy family: Past, Present, and future. Mol Ther 23:1. https:\/\/doi.org\/10.1038\/mt.2014.227","journal-title":"Mol Ther"},{"key":"887_CR63","doi-asserted-by":"publisher","first-page":"9634","DOI":"10.1093\/nar\/gkt725","volume":"41","author":"ME \u00d8stergaard","year":"2013","unstructured":"\u00d8stergaard ME, Southwell AL, Kordasiewicz H, Watt AT, Skotte NH, Doty CN et al (2013) Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. Nucleic Acids Res 41:9634\u20139650. https:\/\/doi.org\/10.1093\/nar\/gkt725","journal-title":"Nucleic Acids Res"},{"key":"887_CR64","doi-asserted-by":"publisher","first-page":"117957352210925","DOI":"10.1177\/11795735221092517","volume":"14","author":"MW Ferguson","year":"2022","unstructured":"Ferguson MW, Kennedy CJ, Palpagama TH, Waldvogel HJ, Faull RLM, Kwakowsky A (2022) Current and possible future therapeutic options for huntington\u2019s disease. J Cent Nerv Syst Dis 14:11795735221092517 PMID: 35615642; PMCID: PMC9125092","journal-title":"J Cent Nerv Syst Dis"},{"key":"887_CR65","doi-asserted-by":"crossref","unstructured":": August Estevez\u2013Huntington\u2019s Disease Clinical Trials Corner, Fraga C, Tabrizi SJ, Wild EJJ, Huntington\u2019s (2023) Dis. 2023;12(2):169\u2013185. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10473124\/ \u2014 This article includes NCT03761849 GENERATION HD1 and describes study design, dosing regimens, and interim findings from this Phase III trial","DOI":"10.3233\/JHD-239001"},{"key":"887_CR66","unstructured":"Hoffmann-La R (2018) A study to evaluate the efficacy and safety of intrathecally administered RO7234292 (RG6042) in participants with manifest Huntington\u2019s disease (ClinicalTrials.gov Identifier: NCT03761849). ClinicalTrials.gov.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03761849"},{"key":"887_CR67","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.3390\/ijms21062146","volume":"21","author":"F Marxreiter","year":"2020","unstructured":"Marxreiter F, Stemick J, Kohl Z (2020) Huntingtin Lowering strategies. Int J Mol Sci 21:2146. https:\/\/doi.org\/10.3390\/ijms21062146","journal-title":"Int J Mol Sci"},{"issue":"6","key":"887_CR68","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.3390\/ijms21062146","volume":"21","author":"F Marxreiter","year":"2020","unstructured":"Marxreiter F, Stemick J, Kohl Z (2020) Huntingtin lowering strategies. Int J Mol Sci 21(6):2146. https:\/\/www.gene.com\/patients\/disease-education\/huntingtons-disease","journal-title":"Int J Mol Sci"},{"key":"887_CR69","unstructured":"Meglio M (2025) GENERATION HD2 trial of Huntington agent tominersen amended to include only higher dose. NeurologyLive. https:\/\/www.neurologylive.com\/view\/generation-hd2-trial-huntington-agent-tominersen-amended-include-only-higher-dose"},{"key":"887_CR70","unstructured":"Hoffman M (2021) NeurologyLive\u00ae top stories of 2021: Movement disorders. NeurologyLive. https:\/\/www.neurologylive.com\/view\/neurologylive-top-stories-of-2021-movement-disorders"},{"key":"887_CR71","unstructured":"WaveLife Sciences Ltd (2024) Wave Life Sciences announces positive results from Phase 1b\/2a SELECT-HD trial with first clinical demonstration of allele-selective mutant huntingtin lowering in Huntington\u2019s disease. GlobeNewswire. https:\/\/www.globenewswire.com\/news-release\/2024\/06\/25\/2903685\/0\/en\/Wave-Life-Sciences-Announces-Positive-Results-from-Phase-1b-2a-SELECT-HD-Trial-with-First-Clinical-Demonstration-of-Allele-Selective-Mutant-Huntingtin-Lowering-in-Huntington-s-Dise.html"},{"issue":"7","key":"887_CR72","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/s41593-022-01207-1","volume":"25","author":"J Zhang","year":"2022","unstructured":"Zhang J, Wang T, Qian W, Chen J, Chen W, Chen Y et al (2022) An RNA-targeting CRISPR\u2013Cas13d system alleviates disease-related phenotypes in huntington\u2019s disease models. Nat Neurosci 25(7):1002\u20131013. https:\/\/doi.org\/10.1038\/s41593-022-01207-1","journal-title":"Nat Neurosci"},{"key":"887_CR73","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1038\/mt.2015.157","volume":"23","author":"RK Chaudhary","year":"2015","unstructured":"Chaudhary RK, Patel KA, Patel MK, Joshi RH, Roy I (2015) Inhibition of aggregation of mutant Huntingtin by nucleic acid aptamers in vitro and in a yeast model of huntington\u2019s disease. Mol Ther 23:1912\u20131926. https:\/\/doi.org\/10.1038\/mt.2015.157","journal-title":"Mol Ther"},{"key":"887_CR74","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1021\/acschemneuro.3c00226","volume":"14","author":"S Jain","year":"2023","unstructured":"Jain S, Roy I (2023) Aptamer reduces aggregation of mutant Huntingtin and rescues proteostasis network in Non-Neuronal and neuronal cells. ACS Chem Neurosci 14:2385\u20132395. https:\/\/doi.org\/10.1021\/acschemneuro.3c00226","journal-title":"ACS Chem Neurosci"},{"key":"887_CR75","doi-asserted-by":"publisher","first-page":"12412","DOI":"10.3390\/ijms232012412","volume":"23","author":"C Riccardi","year":"2022","unstructured":"Riccardi C, D\u2019Aria F, Fasano D, Digilio FA, Carillo MR, Amato J et al (2022) Truncated analogues of a G-Quadruplex-Forming aptamer targeting mutant huntingtin: shorter is Better! Int J Mol Sci 23:12412. https:\/\/doi.org\/10.3390\/ijms232012412","journal-title":"Int J Mol Sci"},{"key":"887_CR76","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","volume":"6","author":"RT Eastman","year":"2020","unstructured":"Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S et al (2020) Remdesivir: A review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent Sci 6:672\u2013683. https:\/\/doi.org\/10.1021\/acscentsci.0c00489","journal-title":"ACS Cent Sci"},{"key":"887_CR77","doi-asserted-by":"publisher","first-page":"117557","DOI":"10.1016\/j.biopha.2024.117557","volume":"180","author":"J Yao","year":"2024","unstructured":"Yao J, Liu T, Hu X, Sheng H, Chen Z, Zhao H et al (2024) An insight into allele-selective approaches to Lowering mutant Huntingtin protein for huntington\u2019s disease treatment. Biomed Pharmacother 180:117557. https:\/\/doi.org\/10.1016\/j.biopha.2024.117557","journal-title":"Biomed Pharmacother"},{"key":"887_CR78","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1111\/bcp.16202","volume":"90","author":"L Gao","year":"2024","unstructured":"Gao L, Bhattacharyya A, Beers B, Kaushik D, Bredlau A, Kristensen A et al (2024) Pharmacokinetics and pharmacodynamics of PTC518, an oral Huntingtin Lowering splicing modifier: A first-in\u2010human study. Br J Clin Pharmacol 90:3242\u20133251. https:\/\/doi.org\/10.1111\/bcp.16202","journal-title":"Br J Clin Pharmacol"},{"key":"887_CR79","unstructured":"Fox L (2022) Sad news from Novartis: Dosing suspended in VIBRANT-HD trial of branaplam. HDBuzz. https:\/\/en.hdbuzz.net\/328\/"},{"key":"887_CR80","unstructured":"PTC Therapeutics Inc (2024) FDA grants Fast Track designation to PTC518 Huntington\u2019s disease program. PR Newswire. https:\/\/ir.ptcbio.com\/news-releases\/news-release-details\/fda-grants-fast-track-designation-ptc518-huntingtons-disease"},{"key":"887_CR81","unstructured":"Skyhawk Therapeutics Inc (2024) Skyhawk Therapeutics to present additional positive topline data from parts A and B of Phase 1 clinical trial of SKY-0515 at European Huntington\u2019s Disease Network and Enroll-HD 2024. PR Newswire. https:\/\/www.prnewswire.com\/news-releases\/skyhawk-therapeutics-to-present-additional-positive-topline-data-from-parts-a-and-b-of-phase-1-clinical-trial-of-sky-0515-at-european-huntingtons-disease-network-and-enroll-hd-2024-302244451.html"},{"issue":"22","key":"887_CR82","doi-asserted-by":"publisher","first-page":"6741","DOI":"10.1021\/jacs.8b01913","volume":"140","author":"MG Costales","year":"2018","unstructured":"Costales MG, Matsumoto Y, Velagapudi SP, Disney MD (2018) Small-molecule targeted recruitment of a nuclease to RNA. J Am Chem Soc 140(22):6741\u20136744. https:\/\/doi.org\/10.1021\/jacs.8b01913","journal-title":"J Am Chem Soc"},{"issue":"5631","key":"887_CR83","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.1082372","volume":"301","author":"M Bibikova","year":"2003","unstructured":"Bibikova M, Beumer K, Trautman JK, Carroll D (2003) Enhancing gene targeting with designed zinc finger nucleases. Science 301(5631):643\u2013647. https:\/\/doi.org\/10.1126\/science.1082372","journal-title":"Science"},{"issue":"7","key":"887_CR84","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","volume":"31","author":"T Gaj","year":"2013","unstructured":"Gaj T, Gersbach CA, Barbas CF, III (2013) ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering. Trends Biotechnol 31(7):397\u2013405. https:\/\/doi.org\/10.1016\/j.tibtech.2013.04.004","journal-title":"Trends Biotechnol"},{"issue":"6","key":"887_CR85","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1073\/pnas.96.6.2758","volume":"96","author":"DJ Segal","year":"1999","unstructured":"Segal DJ, Dreier B, Beerli RR, Barbas CF III (1999) Toward controlling gene expression at will: selection and design of zinc finger domains recognizing each of the 5\u2032-GNN-3\u2032 DNA target sequences. Proc Natl Acad Sci USA 96(6):2758\u20132763. https:\/\/doi.org\/10.1073\/pnas.96.6.2758","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"887_CR86","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/nbt.1948","volume":"29","author":"R Gabriel","year":"2011","unstructured":"Gabriel R, Lombardo A, Arens A, Miller JC, Genovese P, Kaeppel C et al (2011) An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nat Biotechnol 29(9):816\u2013823. https:\/\/doi.org\/10.1038\/nbt.1948","journal-title":"Nat Biotechnol"},{"issue":"2","key":"887_CR87","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nbt.1755","volume":"29","author":"JC Miller","year":"2011","unstructured":"Miller JC, Tan S, Qiao G, Barlow KA, Wang J, Xia DF et al (2011) A TALE nuclease architecture for efficient genome editing. Nat Biotechnol 29(2):143\u2013148. https:\/\/doi.org\/10.1038\/nbt.1755","journal-title":"Nat Biotechnol"},{"issue":"7","key":"887_CR88","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/nbt1314","volume":"25","author":"JC Miller","year":"2007","unstructured":"Miller JC, Holmes MC, Wang J, Guschin DY, Lee YL, Rupniewski I et al (2007) An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol 25(7):778\u2013785. https:\/\/doi.org\/10.1038\/nbt1314","journal-title":"Nat Biotechnol"},{"issue":"10","key":"887_CR89","doi-asserted-by":"publisher","first-page":"5528","DOI":"10.1073\/pnas.100101597","volume":"97","author":"RR Beerli","year":"2000","unstructured":"Beerli RR, Segal DJ, Dreier B, Barbas CF III (2000) Toward controlling gene expression at will: specific regulation of the erbB-2\/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular Building blocks. Proc Natl Acad Sci USA 97(10):5528\u20135533. https:\/\/doi.org\/10.1073\/pnas.100101597","journal-title":"Proc Natl Acad Sci USA"},{"key":"887_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omtn.2019.06.002","volume":"17","author":"M Garriga-Canut","year":"2019","unstructured":"Garriga-Canut M, Agustin-Pavon C, Herrmann C, Torres-Quesada O, Esteller M (2019) Allele-specific targeting of mutant Huntingtin using engineered zinc finger proteins. Mol Therapy \u2013 Nucleic Acids 17:1\u201312. https:\/\/doi.org\/10.1016\/j.omtn.2019.06.002","journal-title":"Mol Therapy \u2013 Nucleic Acids"},{"issue":"21","key":"887_CR91","doi-asserted-by":"publisher","first-page":"11997","DOI":"10.1073\/pnas.2035056100","volume":"100","author":"W Peng","year":"2003","unstructured":"Peng W et al (2003) Zinc-finger protein-targeted gene regulation: genomewide single-gene specificity. Proc Natl Acad Sci U S A 100(21):11997\u201312002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"887_CR92","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3233\/JHD-220566","volume":"11","author":"E Sapp","year":"2022","unstructured":"Sapp E et al (2022) Preclinical development of zinc finger transcriptional repressors for huntington\u2019s disease. J Huntington\u2019s Disease 11(3):457\u2013470. https:\/\/doi.org\/10.3233\/JHD-220566","journal-title":"J Huntington\u2019s Disease"},{"issue":"1","key":"887_CR93","doi-asserted-by":"publisher","first-page":"111953","DOI":"10.1016\/j.celrep.2022.111953","volume":"42","author":"K Khalili","year":"2023","unstructured":"Khalili K et al (2023) Neuronal and astrocytic contributions to huntington\u2019s disease dissected with zinc finger protein transcriptional repressors. Cell Rep 42(1):111953. https:\/\/doi.org\/10.1016\/j.celrep.2022.111953","journal-title":"Cell Rep"},{"issue":"12","key":"887_CR94","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/j.chembiol.2021.08.009","volume":"28","author":"X Jin","year":"2021","unstructured":"Jin X, Hiebert SW (2021) Emerging strategies for gene regulation using engineered DNA-binding proteins: from zinc fingers to CRISPR\/Cas and beyond. Cell Chem Biology 28(12):1538\u20131552. https:\/\/doi.org\/10.1016\/j.chembiol.2021.08.009","journal-title":"Cell Chem Biology"},{"issue":"1","key":"887_CR95","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrm3486","volume":"14","author":"JK Joung","year":"2013","unstructured":"Joung JK, Sander JD (2013) TALENs: A widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol 14(1):49\u201355. https:\/\/doi.org\/10.1038\/nrm3486","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"887_CR96","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/nbt.3481","volume":"34","author":"CD Richardson","year":"2016","unstructured":"Richardson CD, Ray GJ, DeWitt MA, Curie GL, Corn JE (2016) Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA. Nat Biotechnol 34(3):339\u2013344. https:\/\/doi.org\/10.1038\/nbt.3481","journal-title":"Nat Biotechnol"},{"issue":"12","key":"887_CR97","doi-asserted-by":"publisher","first-page":"5429","DOI":"10.1128\/jb.169.12.5429-5433.1987","volume":"169","author":"Y Ishino","year":"1987","unstructured":"Ishino Y, Shinagawa H, Makino K, Amemura M, Nakata A (1987) Nucleotide sequence of the Iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of a new insertion sequence. J Bacteriol 169(12):5429\u20135433. https:\/\/doi.org\/10.1128\/jb.169.12.5429-5433.1987","journal-title":"J Bacteriol"},{"issue":"6096","key":"887_CR98","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E (2012) A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337(6096):816\u2013821. https:\/\/doi.org\/10.1126\/science.1225829","journal-title":"Science"},{"issue":"11","key":"887_CR99","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F (2013) Genome engineering using the CRISPR-Cas9 system. Nat Protoc 8(11):2281\u20132308 https:\/\/doi.org\/10.1038\/nprot.2013.143","journal-title":"Nat Protoc"},{"issue":"1","key":"887_CR100","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1080\/10717544.2018.1474964","volume":"25","author":"CA Lino","year":"2018","unstructured":"Lino CA, Harper JC, Carney JP, Timlin JA (2018) Delivering CRISPR: A review of the challenges and approaches. Drug Delivery 25(1):1234\u20131257. https:\/\/doi.org\/10.1080\/10717544.2018.1474964","journal-title":"Drug Delivery"},{"issue":"4","key":"887_CR101","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41551-021-00721-9","volume":"5","author":"P Wang","year":"2021","unstructured":"Wang P, Zhang L, Zheng W, Cong L, Guo Z, Xie Y, Tang R (2021) Therapeutic genome editing for cancer using CRISPR\u2013Cas9 delivered by lipid nanoparticles. Nat Biomedical Eng 5(4):366\u2013378 https:\/\/doi.org\/10.1038\/s41551-021-00721-9","journal-title":"Nat Biomedical Eng"},{"issue":"7","key":"887_CR102","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1172\/JCI92087","volume":"127","author":"S Yang","year":"2017","unstructured":"Yang S, Chang R, Yang H, Zhao T, Hong Y, Kong HE, Li S (2017) CRISPR\/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington\u2019s disease. J Clin Invest 127(7):2719\u20132724 https:\/\/doi.org\/10.1172\/JCI90969","journal-title":"J Clin Invest"},{"issue":"20","key":"887_CR103","doi-asserted-by":"publisher","first-page":"4566","DOI":"10.1093\/hmg\/ddw287","volume":"25","author":"JW Shin","year":"2016","unstructured":"Shin JW, Kim KH, Chao MJ, Atwal RS, Gillis T, MacDonald ME, Hayden MR (2016) Permanent inactivation of huntington\u2019s disease mutation by personalized allele-specific CRISPR\/Cas9. Hum Mol Genet 25(20):4566\u20134576. https:\/\/doi.org\/10.1093\/hmg\/ddw287","journal-title":"Hum Mol Genet"},{"issue":"6","key":"887_CR104","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","volume":"157","author":"PD Hsu","year":"2014","unstructured":"Hsu PD, Lander ES, Zhang F (2014) Development and applications of CRISPR-Cas9 for genome engineering. Cell 157(6):1262\u20131278. https:\/\/doi.org\/10.1016\/j.cell.2014.05.010","journal-title":"Cell"},{"issue":"5","key":"887_CR105","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s13238-015-0153-5","volume":"6","author":"P Liang","year":"2015","unstructured":"Liang P, Xu Y, Zhang X, Ding C, Huang R, Zhang Z, Huang J (2015) CRISPR\/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell 6(5):363\u2013372. https:\/\/doi.org\/10.1007\/s13238-015-0153-5","journal-title":"Protein Cell"},{"issue":"2","key":"887_CR106","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.stem.2012.12.001","volume":"12","author":"MC An","year":"2018","unstructured":"An MC, Zhang N, Scott G, Montoro D, Wittkop T, Mooney S, Ellerby LM (2018) Genetic correction of Huntington\u2019s disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 12(2):218\u2013229 https:\/\/doi.org\/10.1016\/j.stem.2012.12.001","journal-title":"Cell Stem Cell"},{"issue":"8","key":"887_CR107","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.4380","volume":"23","author":"AM Monteys","year":"2017","unstructured":"Monteys AM, Ebanks SA, Keiser MS, Davidson BL (2017) CRISPR\/Cas9 editing of the mutant Huntingtin allele in vitro and in vivo. Nat Med 23(8):938\u2013947. https:\/\/doi.org\/10.1038\/nm.4380","journal-title":"Nat Med"},{"issue":"12","key":"887_CR108","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1016\/j.celrep.2017.08.075","volume":"20","author":"N Merienne","year":"2017","unstructured":"Merienne N, Vachey G, de Longprez L, Meunier C, Zimmer V, Perriard G, Canales M, Mathias A, Herrgott L, Beltraminelli T, Maulet Y, D\u00e9glon N (2017) The self-inactivating KamiCas9 system for the editing of CNS disease genes. Cell Rep 20(12):2980\u20132991. https:\/\/doi.org\/10.1016\/j.celrep.2017.08.075","journal-title":"Cell Rep"},{"issue":"6230","key":"887_CR109","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1126\/science.aaa4327","volume":"348","author":"D Baltimore","year":"2015","unstructured":"Baltimore D, Berg P, Botchan M, Carroll D, Charo RA, Church G, Corn JE, Daley GQ, Doudna JA, Fenner M, Greely H, Jinek M, Martin G, Penhoet E, Puck J, Sternberg SH, Weissman JS, Yamamoto KR, Hamilton RS (2015) A prudent path forward for genomic engineering and germline gene modification. Science 348(6230):36\u201338. https:\/\/doi.org\/10.1126\/science.aaa4327","journal-title":"Science"},{"key":"887_CR110","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/519410a","volume":"519","author":"E Lanphier","year":"2015","unstructured":"Lanphier E, Urnov F, Haecker SE, Werner M, Smolenski J (2015) Don\u2019t edit the human germ line. Nature 519:410\u2013411. https:\/\/doi.org\/10.1038\/519410a","journal-title":"Nature"},{"issue":"1","key":"887_CR111","doi-asserted-by":"publisher","first-page":"Article112","DOI":"10.1038\/s42003-023-04829-8","volume":"6","author":"JH Seo","year":"2023","unstructured":"Seo JH, Shin JH, Lee J, Kim D, Hwang H-Y, Nam B-G, Cho S-R (2023) DNA double-strand break-free CRISPR interference delays huntington\u2019s disease progression in mice. Commun Biology 6(1):Article112. https:\/\/doi.org\/10.1038\/s42003-023-04829-8","journal-title":"Commun Biology"},{"issue":"9","key":"887_CR112","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1002\/jnr.25042","volume":"100","author":"ST Lee","year":"2022","unstructured":"Lee ST, Im W, Ban JJ, Lee M, Jung K, Lee SK, Chu K (2022) CRISPR\/Cas9-mediated genome editing of huntington\u2019s disease neurospheres. J Neurosci Res 100(9):2239\u20132252. https:\/\/doi.org\/10.1002\/jnr.25042","journal-title":"J Neurosci Res"},{"issue":"12","key":"887_CR113","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.tips.2018.09.002","volume":"39","author":"DE Ehrnhoefer","year":"2018","unstructured":"Ehrnhoefer DE, Sutton L, Hayden MR (2018) Small molecules, big impact: autophagy enhancers in huntington\u2019s disease. Trends Pharmacol Sci 39(12):1025\u20131038. https:\/\/doi.org\/10.1016\/j.tips.2018.09.002","journal-title":"Trends Pharmacol Sci"},{"issue":"10","key":"887_CR114","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1038\/s41563-024-02114-5","volume":"24","author":"Y Lin","year":"2025","unstructured":"Lin Y et al (2025) Blood\u2013brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system. Nat Mater 24(10):1653\u20131663","journal-title":"Nat Mater"},{"key":"887_CR115","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/s12951-021-00810-x","volume":"19","author":"O Duan","year":"2021","unstructured":"Duan O, Ouyang X, Xu X, Wen Y, Zhou Q, Qin Z et al (2021) Nanoparticle delivery of CRISPR\/Cas9 for genome editing: challenges and prospects. J Nanobiotechnol 19:356","journal-title":"J Nanobiotechnol"},{"issue":"11","key":"887_CR116","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/s41591-019-0478-3","volume":"25","author":"M Garriga-Canut","year":"2019","unstructured":"Garriga-Canut M, Agust\u00edn-Pavon C, Herrmann C, Torres-Quesada O, Esteller M (2019) Allele-selective transcriptional repression of mutant HTT for the treatment of huntington\u2019s disease. Nat Med 25(11):1859\u20131869. https:\/\/doi.org\/10.1038\/s41591-019-0478-3","journal-title":"Nat Med"},{"issue":"21","key":"887_CR117","doi-asserted-by":"publisher","first-page":"9634","DOI":"10.1093\/nar\/gkt751","volume":"41","author":"CS Sullivan","year":"2013","unstructured":"Sullivan CS et al (2013) Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele-selective suppression of mutant Huntingtin in the CNS. Nucleic Acids Res 41(21):9634\u20139649. https:\/\/doi.org\/10.1093\/nar\/gkt751","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"887_CR118","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S1474-4422(17)30120-0","volume":"16","author":"LM Byrne","year":"2017","unstructured":"Byrne LM, Rodrigues FB, Blennow K, Zetterberg H, Barker RA, Wild EJ (2017) Neurofilament light protein in blood as a potential biomarker of neurodegeneration in huntington\u2019s disease: A retrospective cohort analysis. Lancet Neurol 16(8):601\u2013609. https:\/\/doi.org\/10.1016\/S1474-4422(17)30120-0","journal-title":"Lancet Neurol"},{"issue":"5","key":"887_CR119","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1172\/JCI80743","volume":"125","author":"EJ Wild","year":"2015","unstructured":"Wild EJ, Boggio R, Langbehn D, Robertson N, Haider S, Miller J, Tabrizi SJ (2015) Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington\u2019s disease patients. J Clin Invest 125(5):1979\u20131986 https:\/\/doi.org\/10.1172\/JCI80188","journal-title":"J Clin Invest"},{"key":"887_CR120","doi-asserted-by":"publisher","unstructured":"Tabrizi, S. J., Scahill, R. I., Owen, G., Durr, A., Leavitt, B. R., Roos, R. A.,\u2026 TRACK-HD Investigators. (2013). Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington\u2019s disease in the TRACK-HD study: Analysis of 36-month observational data. The Lancet Neurology, 12(7), 637\u2013649. https:\/\/doi.org\/10.1016\/S1474-4422(13)70088-7","DOI":"10.1016\/S1474-4422(13)70088-7"},{"issue":"9","key":"887_CR121","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1038\/ng.3907","volume":"49","author":"DJH Moss","year":"2017","unstructured":"Moss DJH, Pardi\u00f1as AF, Langbehn D, Lo K, Leavitt BR, Roos R, Tabrizi SJ (2017) Identification of genetic variants associated with huntington\u2019s disease progression and CAG repeat instability. Nat Genet 49(9):1291\u20131299. https:\/\/doi.org\/10.1038\/ng.3907","journal-title":"Nat Genet"},{"issue":"3","key":"887_CR122","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41593-022-01013-3","volume":"25","author":"S Yang","year":"2022","unstructured":"Yang S, Chang R, Yang H, Zhao T, Hong Y, Kong HE, Li X-J (2022) RNA-targeting CRISPR\u2013Cas13d alleviates disease-related phenotypes in Huntington\u2019s disease mice. Nat Neurosci 25(3):349\u2013360 https:\/\/doi.org\/10.1038\/s41593-022-01013-3","journal-title":"Nat Neurosci"},{"issue":"690","key":"887_CR123","doi-asserted-by":"publisher","first-page":"eabq9186","DOI":"10.1126\/scitranslmed.abq9186","volume":"15","author":"S Yan","year":"2023","unstructured":"Yan S, Tu Z, Yang S, Yang H, Hong Y, Kong HE, Li X-J (2023) AAV-delivered CRISPR-Cas13d therapy for Huntington\u2019s disease in a large animal model. Sci Transl Med 15(690):eabq9186 https:\/\/doi.org\/10.1126\/scitranslmed.abq9186","journal-title":"Sci Transl Med"},{"issue":"12","key":"887_CR124","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1038\/nmeth.3630","volume":"12","author":"PI Thakore","year":"2015","unstructured":"Thakore PI, D\u2019Ippolito AM, Song L, Safi A, Shivakumar NK, Kabadi AM, Gersbach CA (2015) Highly specific epigenome editing by CRISPR-Cas9 repressors for Silencing of distal regulatory elements. Nat Methods 12(12):1143\u20131149. https:\/\/doi.org\/10.1038\/nmeth.3630","journal-title":"Nat Methods"},{"issue":"5","key":"887_CR125","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/nbt.3199","volume":"33","author":"IB Hilton","year":"2015","unstructured":"Hilton IB, D\u2019Ippolito AM, Vockley CM, Thakore PI, Crawford GE, Reddy TE, Gersbach CA (2015) Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nat Biotechnol 33(5):510\u2013517. https:\/\/doi.org\/10.1038\/nbt.3199","journal-title":"Nat Biotechnol"},{"issue":"2","key":"887_CR126","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","volume":"34","author":"JG Doench","year":"2016","unstructured":"Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, Root DE (2016) Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol 34(2):184\u2013191 https:\/\/doi.org\/10.1038\/nbt.3437","journal-title":"Nat Biotechnol"},{"issue":"1","key":"887_CR127","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13059-018-1459-4","volume":"19","author":"G Chuai","year":"2018","unstructured":"Chuai G, Ma H, Yan J, Chen M, Hong N, Xue D, Liu Q (2018) DeepCRISPR: Optimized CRISPR guide RNA design by deep learning. Genome Biol 19(1):80 https:\/\/doi.org\/10.1186\/s13059-018-1459-4","journal-title":"Genome Biol"},{"issue":"3","key":"887_CR128","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nbt.4061","volume":"36","author":"HK Kim","year":"2018","unstructured":"Kim HK, Min S, Song M, Jung S, Choi JW, Kim Y, Kim HH (2018) Deep learning improves prediction of CRISPR\u2013Cpf1 guide RNA activity. Nat Biotechnol 36(3):239\u2013241. https:\/\/doi.org\/10.1038\/nbt.4061","journal-title":"Nat Biotechnol"},{"issue":"2","key":"887_CR129","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.stem.2012.04.026","volume":"11","author":"MC An","year":"2012","unstructured":"An MC, Zhang N, Scott G, Montoro D, Wittkop T, Mooney S, Ellerby LM (2012) Genetic correction of Huntington\u2019s disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 11(2):253\u2013263 https:\/\/doi.org\/10.1016\/j.stem.2012.04.026","journal-title":"Cell Stem Cell"},{"issue":"4","key":"887_CR130","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.stem.2016.08.008","volume":"19","author":"A Benraiss","year":"2016","unstructured":"Benraiss A, Toner MJ, Xu Q, Bruel-Jungerman E, Rogers EH, Wang F, Goldman SA (2016) Sustained mobilization of endogenous neural progenitors delays disease progression in a Transgenic model of huntington\u2019s disease. Cell Stem Cell 19(4):429\u2013446. https:\/\/doi.org\/10.1016\/j.stem.2016.08.008","journal-title":"Cell Stem Cell"},{"issue":"10","key":"887_CR131","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1038\/s41591-023-02568-1","volume":"29","author":"SJ Tabrizi","year":"2023","unstructured":"Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA, PTC Therapeutics Study Group (2023) Targeting huntingtin mRNA splicing with an oral small-molecule therapy in Huntington\u2019s disease. Nat Med 29(10):2485\u20132495 https:\/\/doi.org\/10.1038\/s41591-023-02568-1","journal-title":"Nat Med"},{"issue":"2","key":"887_CR132","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1136\/jnnp-2021-326126","volume":"93","author":"P McColgan","year":"2022","unstructured":"McColgan P, Tabrizi SJ, Schobel SA, Leavitt BR, Landwehrmeyer GB, Wild EJ (2022) Huntington\u2019s disease: current and future therapeutic prospects. J Neurol Neurosurg Psychiatry 93(2):142\u2013154. https:\/\/doi.org\/10.1136\/jnnp-2021-326126","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Neurogenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10048-026-00887-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10048-026-00887-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10048-026-00887-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T12:09:59Z","timestamp":1779797399000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10048-026-00887-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":132,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["887"],"URL":"https:\/\/doi.org\/10.1007\/s10048-026-00887-2","relation":{},"ISSN":["1364-6753"],"issn-type":[{"value":"1364-6753","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,21]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"17"}}